The evidence on peptides — delivered weekly. Subscribe free →

Cathelicidins

low risk

Also: Cathelicidin family · LL-37 precursor family · CAMP proteins

Moderate Evidence Research Only

Reference entry for cathelicidins — the second major class of human antimicrobial peptides alongside defensins. LL-37 is the only human cathelicidin active form. Other mammals produce multiple cathelicidins. Important in skin barrier function, respiratory defense, and innate immune signaling.

Molecular Weight
2–5 kDa
Formula
Various
Common Dosing
Not standardized; LL-37 is the only human-focused clinical compound
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Antimicrobial / immune defense

Moderate Evidence 67 studies

Well-characterized innate immunity role. Multiple clinical trials ongoing for LL-37 (the human cathelicidin).

Mechanism of Action

C-terminal amphipathic alpha-helical active domains disrupt bacterial and fungal membranes; also modulate TLR signaling, promote wound healing, and have antiviral properties.

LL-37 As the Exemplar

LL-37 is the only processed, active cathelicidin in humans. For clinical detail on cathelicidin pharmacology, see the LL-37 entry. This entry provides taxonomic and biological context for the broader family.

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Dose-dependent cytotoxicity

Contraindications

  • •Autoimmune conditions (theoretical)

Primary Uses

AntimicrobialInnate immunityWound healingImmunomodulation

Related Peptides

ll-37defensinsthymosin-alpha-1

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe Cathelicidins?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.